

29 November 2024

2024 Annual General Meeting Chair's Address

Dear Shareholders,

As Chair of the Board of Directors, I would like to report on a year of significant progress and change for the Company, positioning Bio-Gene for the next pivotal stage of commercialising our active ingredients Qcide® and Flavocide®.

The past twelve months have seen us made significant strides in advancing our mission to bring our proprietary insecticidal products, Qcide® and Flavocide®, closer to commercialisation. These products respond to a growing global need for new pest management solutions as traditional insecticides face resistance issues and regulatory bans on toxic substances.

With more than half the world's population at risk of vector-borne diseases, and annual sales of mosquito insecticides for public health at almost \$1 billion, the opportunity for Bio-Gene and our technologies is very significant. We are also focused on agricultural applications to mitigate crop yield losses and spoilage due to insect infestations, which contribute to significant global food losses valued at approximately US\$2 trillion annually¹.

We have refined our development pipeline to prioritise products with the greatest commercial potential, focusing on strategic areas in public health vector control, crop protection, and consumer applications. With this focus, we are working towards submissions for regulatory approval for Flavocide® and Qcide® with the Australian regulator, developing proprietary manufacturing and production expertise, and continuing our work with strong commercial partners on formulated product development, marketing and distribution.

Our CEO Tim Grogan will speak to this in more detail, but major recent milestones for the Company have included the mosquito management collaboration with Envu, APVMA feedback which sets us on a clear path for our development plan for Flavocide, and most recently reaching a key production milestone for Flavocide with Rallis India.

In terms of personnel, we were delighted to welcome Edmond Tern to the Bio-Gene team as Chief Financial Officer and Joint Company Secretary during the year. Edmond is a respected executive with extensive experience in optimising finance and operations. We are confident that his strong track record with the investment community will be a valuable asset for us.

Financially, Bio-Gene has maintained efficient capital management, and successfully raised A\$2 million to support Flavocide batch production and the development of data for our regulatory dossier.

¹ Oerke EC, Crop Losses to pest J. Agri Sci 144: 31-43 (2005); Pimentel D Pesticides and Pest controls. In: Peshin R, Dhawan AK. (eds). Integrated pest management: innovation-development process, 1:83-87. Springer Science (2009)

29 November 2024

We thank you, our shareholders, for your continued support of the Company, as well as the BioGene team's dedication to driving its continued progress.

We look forward to an important upcoming year with further updates to shareholders on our progress.

For further information, please contact:

Bio-Gene Technology Limited:

E: bgt.info@bio-gene.com.au

Matthew Wright

NWR Communications

E: matt@nwrcommunications.com.au

M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and **Qcide®** are registered trademarks of Bio-Gene Technology Limited in Australia.